Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 23979154.
- Also identified by DOI 10.1172/JCI71220 and PMC identifier 3754277.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a report reading like a fascinating detective story, Vincent and colleagues crack the mysterious case of east Texas bleeding disorder. They show that affected individuals have a mutation in exon 13 of the coagulation F5 gene that causes increased expression of an alternatively spliced transcript, which encodes a previously unrecognized factor V (FV) isoform they call FV-short. This FV isoform lacks a large portion of the B domain of FV, which is normally released upon the proteolytic activation of FV by thrombin and binds tightly to the coagulation regulator tissue factor pathway inhibitor-α (TFPIα). This interaction leads to an approximately 10-fold increase in the level of TFPIα circulating in plasma and a resultant anticoagulant effect that produces a hemorrhagic diathesis.
Medical subject headings
- Blood Coagulation Disorders, Inherited
- Factor V
- Hemorrhagic Disorders
- Lipoproteins